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Abstract
Background: T cell-based interferon-γ (IFN-γ) release assays (IGRAs) are novel tests for latent tuberculosis infection
(LTBI). It has been suggested that T cell responses may be correlated with bacterial burden and, therefore, IGRAs may
have a role in monitoring treatment response. We investigated IFN-γ responses to specific TB antigens among Indian
health care workers (HCWs) before, and after LTBI preventive therapy.
Methods: In 2004, we established a cohort of HCWs who underwent tuberculin skin testing (TST) and a whole-blood
IGRA (QuantiFERON-TB-Gold In-Tube [QFT-G], Cellestis Ltd, Victoria, Australia) at a rural hospital in India. HCWs
positive by either test were offered 6 months of isoniazid (INH) preventive therapy. Among the HCWs who underwent
therapy, we prospectively followed-up 10 nursing students who were positive by both tests at baseline. The QFT-G assay
was repeated 4 and 10 months after INH treatment completion (i.e. approximately 12 months and 18 months after the
initial testing). IFN-γ responses to ESAT-6, CFP-10 and TB7.7 peptides were measured using ELISA, and IFN-γ ≥0.35 IU/
mL was used to define a positive QFT-G test result.
Results: All participants (N = 10) reported direct contact with smear-positive TB patients at baseline, during and after
LTBI treatment. All participants except one started treatment with high baseline IFN-γ responses (median 10.0 IU/mL).
The second QFT-G was positive in 9 of 10 participants, but IFN-γ responses had declined (median 5.0 IU/mL); however,
this difference was not significant (P = 0.10). The third QFT-G assay continued to be positive in 9 of 10 participants, with
persistently elevated IFN-γ responses (median 7.9 IU/mL; P = 0.32 for difference against baseline average).
Conclusion: In an environment with ongoing, intensive nosocomial exposure, HCWs had strong IFN-γ responses at
baseline, and continued to have persistently elevated responses, despite LTBI treatment. It is plausible that persistence
of infection and/or re-infection might account for this phenomenon. Our preliminary findings need confirmation in larger
studies in high transmission settings. Specifically, research is needed to study T cell kinetics during LTBI treatment, and
determine the effect of recurrent exposures on host cellular immune responses.
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Background
The World Health Organization (WHO) has estimated
that approximately one third of the world's population is
infected with Mycobacterium tuberculosis [1,2]. This large
pool of individuals with latent infection poses a major
hurdle for global tuberculosis (TB) control efforts.
Between 8 and 9 million people develop TB disease each
year, and about 2 million die from TB every year [1,3].
Until recently, the only tool available to detect latent
tuberculosis infection (LTBI) was the tuberculin skin test
(TST). Although the TST is useful in clinical practice, it has
several known limitations, including variable specificity,
cross-reactivity with BCG vaccine and non-tuberculous
mycobacterial (NTM) infection, and problems with relia-
bility [4-6].
Because of advances in molecular biology and genomics,
for the first time, an alternative has emerged in the form
of a new class of T cell-based, in vitro assays that measure
interferon-γ (IFN-γ) released by sensitized T cells after
stimulation by Mycobacterium tuberculosis antigens [7-10].
Early versions of IFN-γ release assays (IGRAs) used puri-
fied protein derivative (PPD) as the stimulating antigen,
but these tests have been replaced by newer versions that
use antigens (early secreted antigenic target 6 [ESAT-6]
and culture filtrate protein 10 [CFP-10]) that are more
specific to M. tuberculosis than PPD. These antigens,
encoded by genes located within the region of difference
1 (RD1) segment of the M. tuberculosis genome, are more
specific because they are not shared with any of the BCG
vaccine strains or certain species of NTM [11,12].
Two IGRAs are now available as commercial kits: the T-
SPOT.TB® test (Oxford Immunotec, Oxford, UK), and the
QuantiFERON®-TB Gold® (Cellestis Ltd, Carnegie, Aus-
tralia) assay. The QuantiFERON®-TB Gold (QFT-G) assay
is available in two formats, a 24-well culture plate format
(approved by the US Food and Drug Administration
[FDA] [13]), and a newer, simplified In Tube format (not
FDA approved as yet; but available in other countries
[14]). The T-SPOT.TB test is currently CE marked for use
in Europe.
Research evidence, extensively reviewed elsewhere [7-
10,13-15], suggests that IGRAs are more specific than TST,
better correlated with markers of TB exposure in low inci-
dence settings, and less affected by BCG vaccination than
the TST. In the US, the Centers for Disease Control and
Prevention (CDC) has recommended that QFT-G can be
used in place of the TST for all indications, including
screening of contacts, immigrants, and health care work-
ers [13]. In the UK, the National Institute for Health and
Clinical Excellence (NICE) Tuberculosis guidelines rec-
ommend a two-step strategy for LTBI diagnosis: initial
screen with TST, and those who are positive (or in whom
TST may be unreliable) should then be considered for
IGRA testing, if available, to confirm positive TST results
[16].
Although IGRAs are promising and offer several logistical
advantages [7,8,13,14], unresolved issues remain
[7,8,10,13,17,18]. One area of controversy is whether
they can be used for monitoring treatment responses
[7,8,10]. It has been hypothesized that short incubation
assays (e.g. both commercial assays use 16 – 24 hours
incubation) detect responses of partially activated, effec-
tor T cells that have recently encountered antigens in vivo,
and can therefore rapidly release IFN-γ when stimulated in
vitro  [19,20]. In contrast, long-lived central memory T
cells that may persist even after clearance of the organism
(e.g. previously treated TB) are less likely to release IFN-γ
with short incubation [20]. Effector response may be
driven by the antigen load, and there is evidence that
reduction of the antigen load by treatment decreases T cell
responses [19,20].
Although studies have examined the effect of active TB
treatment on IFN-γ responses, the results have been incon-
sistent. As reviewed elsewhere [7,8], some studies have
shown declining responses after treatment, whereas oth-
ers have shown unchanging, fluctuating, or increasing
responses over treatment. It is plausible that variations in
incubation periods (short vs. long), antigens (proteins vs.
peptides), and assay formats (ELISA vs. ELISPOT) might
explain some of the discrepancies [7,8]. In contrast to
active TB, limited data exist on T cell responses after LTBI
preventive therapy [21,22]. In this preliminary report, we
present data on T cell responses before and after preven-
tive therapy among health care workers (HCWs) in rural
India. TB is an important but poorly studied occupational
risk among Indian HCWs [23-25]. As in the case of most
developing countries, infection control measures are
rarely used in Indian hospitals, and HCWs tend to get
repeatedly exposed to smear-positive TB patients. How-
ever, not much research has been conducted using newer
IGRAs among HCWs who work in high incidence coun-
tries.
Methods
Description of the study cohort
In early 2004, we established a cohort of 726 HCWs
(median age, 22 years; 62% women) who underwent TST
and QFT-G In-Tube testing at a rural medical school hos-
pital in India [23]. This hospital has a high TB case load,
and like most hospitals in India, repeated exposure to TB
is common among HCWs [23]. Our cohort of 726 HCWs
was comprised of 353 (49%) medical students and nurs-
ing students, 73 (10%) interns and residents, 161 (22%)
nurses, 13 (2%) attending physicians/faculty, and 126Journal of Occupational Medicine and Toxicology 2006, 1:7 http://www.occup-med.com/content/1/1/7
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(17%) orderlies and laboratory workers. About 71% of
the cohort had BCG vaccine scars, and only 5% had
received TST prior to the baseline study. At baseline, of the
726 HCWs, 68% reported having had at least one direct
contact with a patient with TB (direct contact was defined
as contact between two people that is of sufficient distance
to allow conversation between them [26]).
Tuberculin skin test and QuantiFERON-TB Gold In Tube 
assay
At baseline, all HCWs underwent a TST (Mantoux tech-
nique) using 1 TU PPD RT23, the standard dose in India
[27]. 1 TU of the PPD was administered on the volar sur-
face of the forearm by a certified technician using the
Mantoux method. The maximum transverse diameter of
the induration was read after 48 – 72 hours using a
blinded caliper. IFN-γ responses to ESAT-6, CFP-10, and
TB7.7 (Rv2654) were measured by the QFT-G In Tube
assay, as per the manufacturer's instructions (Cellestis
Limited, Victoria, Australia).
The QFT-G In Tube assay involved two stages: (1) incuba-
tion of whole blood with antigens, and (2) measurement
of IFN-γ production in harvested plasma by ELISA.
Venous blood was directly collected into three 1 mL
heparin-containing tubes. One tube contained only
heparin as negative control, another also contained the T-
cell mitogen phytohemagglutinin as positive control, and
the third tube had overlapping peptides representing the
entire sequences of ESAT-6 and CFP-10 and another pep-
tide from the TB antigen TB7.7 (Rv2654). Within 2 – 6
hours of blood draw, the tubes were incubated at 37°C.
After 24 hours of incubation, the tubes were centrifuged
and plasma was harvested and frozen at -70°C until the
ELISA was performed. The amount of IFN-γ was quanti-
fied using the QFT ELISA. The ELISA readout was analyzed
using the QFT-G software. IFN-γ values (International
Units [IU] per mL) for TB-specific antigens and mitogen
were corrected for background by subtracting the value
obtained for the respective negative control.
As recommended by the manufacturer and used in previ-
ous studies [23,24,28-30], an IFN-γ ≥0.35 IU/mL for (TB
antigens – Negative control) was considered indicative of
TB infection. For a QFT-G result to be valid, the (Mitogen
– Negative control) must be = 0.5 IU/mL and/or (TB anti-
gens – Negative control) must be ≥ 0.35 IU/mL. All assays
were deemed valid, and met the internal quality stand-
ards. No indeterminate results were reported.
Cohort follow-up
As reported previously [23], at baseline (in 2004), valid
TST results were available for 720 of 726 HCWs, and valid
QFT-G results were available for 725 of 726 HCWs. The
baseline prevalence estimates of TST and QFT-positivity
were comparable (41% [95% CI 38% – 45%] and 40%
[95% CI 37% – 43%], respectively). Baseline agreement
between TST and QFT-G was high (81%, κ = 0.61 [95% CI
0.56–0.67]). Increasing age and years in the health profes-
sion were significant risk factors for both QFT and TST
Table 1: T cell interferon-γ responses in nursing students treated for latent tuberculosis infection with isoniazid preventive therapy for 
6 months (N = 10)
ID 
number
Age at 
baseline
Sex 
M/F
BCG 
scar (Y/
N)
TST at 
baseline 
(mm)
IFN-γ responses at baseline 
(Jan/Feb 2004)
IFN-γ responses at second 
survey, 4 months after INH 
treatment (Jan 2005)
IFN-γ responses at third 
survey, 10 months after INH 
treatment (July 2005)
Result 
(Pos/Neg)*
IU/mL** Result 
(Pos/Neg)*
IU/mL** Result 
(Pos/Neg)*
IU/mL**
10055 19 F Y 14 P 10.0 P 10.0 P 10.0
10066 19 F Y 15 P 10.0 P 2.55 P 10.0
10069 19 F Y 17 P 9.55 P 10.0 P 10.0
10077 19 F N 19 P 10.0 P 4.34 P 2.04
10082 19 F Y 18 P 10.0 P 10.0 P 5.86
10089 19 F Y 16 P 10.0 P 8.35 P 1.51
10093 19 F N 20 P 10.0 P 5.13 P 3.31
10115 24 F Y 17 P 0.39 N 0 N 0.21
10282 19 F N 15 P 1.21 P 4.40 P 10.0
10290 18 F N 18 P 10.0 P 4.81 P 10.0
Mean 
(SD)
8.1 (3.9) 5.9 (3.5) 6.3 (4.2)
Median 10.0 5.0 7.9
*QFT-G cut-point for positivity: ≥0.35 IU/mL
** IFN-γ values >10.0 IU/mL have been shown as 10 IU/mL
TST: tuberculin skin test; QFT-G: QuantiFERON-TB Gold In Tube assay; INH: isoniazid; BCG: bacille Calmette-Guerin; SD: standard deviationJournal of Occupational Medicine and Toxicology 2006, 1:7 http://www.occup-med.com/content/1/1/7
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positivity. Since 2004, this HCW cohort has been under
follow-up. Notably, a repeat survey of this cohort in 2005
showed a high annual risk of TB infection (ARTI) among
young trainees at this hospital [24]; the ARTI was esti-
mated to be 5%, and this rate is higher than the popula-
tion average of 1.5% for India [31].
After baseline testing in 2004, individuals positive by
either TST or QFT-G were offered 6 months of standard
isoniazid (INH) as preventive therapy. At baseline, 360 of
726 (50%) HCWs were positive by either TST or QFT-G
[23]. However, only 61 (17%) accepted INH, and 35
(10%) completed treatment.
In January 2005, 22 nursing students who had undergone
baseline testing in January/February 2004, and had com-
pleted INH treatment 4 months earlier, underwent a fol-
low-up QFT-G. These students underwent a third QFT-G
in July 2005, 10 months after treatment. Of the 22 stu-
dents, 10 students were TST and QFT-G positive at base-
line (i.e. TST+/QFT-G+), and underwent both follow-up
QFT-G tests. These students also completed question-
naires on their work patterns and TB exposure during the
follow-up. Identical assay protocols were used for all QFT-
G tests, and follow-up assays were performed blinded to
the previous results. Because these HCWs were TST-posi-
tive at baseline, they were not asked to undergo repeat
tuberculin skin testing. All participants gave informed
consent, and the research protocol was approved by ethics
committees in India and USA [23].
Statistical analyses
Data were analyzed using Stata 9 (Stata Corp, Texas, USA).
The main outcome was effect of treatment on QFT-G
results, expressed as dichotomous (positive/negative) and
continuous measures (IFN-γ expressed as IU/mL). Because
the QFT-G ELISA cannot accurately measure IFN-γ values
>10 IU/mL, values >10 IU/mL were treated as 10 IU/mL
in all the analyses. Differences between average IFN-γ lev-
els were analyzed using the Wilcoxon signed-rank test.
Results
All the participants (N = 10) were female nursing students
(median age 19 years, range 18 to 24), and reported direct
contact (pragmatically defined as contact between two
people that is of sufficient distance to allow conversation
between them [23,26]) with smear-positive TB patients at
baseline, during and after LTBI treatment. All participants
were TST and QFT-G positive at baseline (in 2004), and all
had completed INH treatment with good adherence. The
median baseline TST induration was 17 mm (range 14 to
20 mm), and 6 of 10 (60%) participants had BCG scars.
As seen in the Table and Figure, all participants except one
started treatment with high baseline IFN-γ responses
(median 10.0 IU/mL, after correcting for the background).
The second QFT-G assay was positive in 9 of 10 (90%)
participants, but IFN-γ responses had declined (median
5.0 IU/mL); however, this difference was not statistically
significant (P = 0.10). The third QFT-G assay continued to
be positive in 9 of 10 (90%) participants, with persistently
elevated IFN-γ responses (median 7.9); P = 0.32 for differ-
ence against the baseline average. Only one participant
had a reversion; this individual had a baseline response of
0.39 IU/mL, just above the diagnostic threshold of 0.35
IU/mL.
Discussion
In latent TB infection, bacterial burden is low, and preven-
tive therapy with a single drug (isoniazid) for 6–9 months
is considered adequate to prevent active disease [32,33].
However, currently there is no test or surrogate marker to
monitor response to LTBI preventive therapy. Also, there
is no reliable test that can detect new exogenous TB infec-
tion after successful clearance of the original infection. An
association between INH treatment and tuberculin rever-
sions has been reported in the past [34,35], and based on
the results of some studies that showed declining IFN-γ
responses after active TB treatment [36-39], it is plausible
that INH treatment might decrease IFN-γ responses. In
contrast to active TB, the kinetics of T cell responses dur-
ing LTBI treatment has not been well studied, and, to our
knowledge, this is the first report of longitudinal changes
in IFN-γ responses after LTBI treatment among HCWs in a
high burden, developing country, measured using the lat-
est In Tube version of the QFT-G assay.
In a recent study from Japan, 37 HCWs underwent QFT-G
assays after INH for 6 months [21]. Although many HCWs
continued to remain QFT-G positive, IFN-γ levels were sig-
nificantly lower soon after treatment: ESAT-6 responses
decreased from 3.36 ± 4.97 to 1.21 ± 2.23 IU/mL; CFP-10
responses decreased from 1.69 ± 3.15 to 0.23 ± 2.04 IU/
mL [21]. The authors speculated that it might take longer
than 6 months for clearance of infection, and recom-
mended longer follow-up.
In another recent study, healthy TST-positive immigrants
in the UK underwent an ELISPOT assay at the beginning,
during, and end of INH and rifampicin for 12 weeks [22].
Treatment resulted in a 1.8 fold rise in the numbers of
IFN-γ producing T cells within 26 ± 4 days of starting treat-
ment, followed by a decrease to below baseline by the end
of treatment [22]. There was no significant overall change
in T cell responses in an untreated group.
Our study, although limited by the small numbers, and
lack of an untreated control group, offers a different per-
spective, because it was conducted in a nosocomial setting
in a high-prevalence country. Almost all HCWs in ourJournal of Occupational Medicine and Toxicology 2006, 1:7 http://www.occup-med.com/content/1/1/7
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study had persistent high T cell IFN-γ responses, even 10
months after treatment completion. Although there was a
modest decline in the average IFN-γ responses after treat-
ment, the post-treatment responses remained substan-
tially higher than the diagnostic threshold. It is possible
that some of the observed changes were due to regression
to the mean, or to random variability. The only partici-
pant who had a reversion, had a low baseline IFN-γ
response, close to the threshold. This finding is consistent
with our previous follow-up study of this HCW cohort
[24]. In the absence of any longitudinal data on out-
comes, it is not clear if individuals with high T cell
responses after treatment are at greater or lesser risk of
progressing to disease. Long-term follow-up of large
cohorts are needed to answer these questions.
In the absence of a strong evidence base on this topic, we
put forth several tentative hypotheses that might explain
our findings. First, in high incidence settings, individuals
with LTBI may have very strong IFN-γ responses at diagno-
sis. In fact, 80% of our participants had baseline values
≥10 IU/mL, much higher than those reported from Japan
[21]. Therefore, unless the IFN-γ levels drop drastically,
QFT-G reversions are unlikely, even after treatment. Sec-
ond, it is possible, that in HCWs repeatedly exposed to TB,
6 months of INH is inadequate to clear the infection. INH
resistance might influence this. In India, about 10% of
newly diagnosed smear-positive TB patients have INH
resistance [40]. It will be interesting to do similar experi-
ments after the longer, 9 month INH regimen, or alterna-
tive LTBI regimens (e.g. rifampin for 4 months).
Third, ongoing exposure and/or exogenous re-infection
might keep the effector T cells partially activated, and
therefore T cell responses remain robust even after antigen
load declines with therapy. Interestingly, some individu-
als had a transient decline in T cell responses shortly after
treatment, but much higher responses subsequently. It is
plausible that these individuals became re-infected after
successful clearance of their primary infection. Studies in
high incidence settings are required to address these
intriguing questions, but will be challenging to conduct
because of potential confounders such as malnutrition,
BCG vaccination, non-tuberculous mycobacteria, and
tropical infections (e.g. helminthiasis). In low incidence
settings (e.g. Japan and UK), it is possible that treatment
might cause steeper declines in IFN-γ responses [21,22].
Fourth, the duration of follow-up in our study may have
been inadequate. It might take longer for IFN-γ levels to
decline to negativity after treatment [21]. However, in
high incidence countries where recurrent exposure is
widespread, IFN-γ responses may not disappear, even
with longer follow-up. Fifth, exposure to certain non-
tuberculous (environmental) mycobacteria (e.g. M. mari-
num) may play a role in inducing T cell responses, even
after clearance of the original M. tuberculosis infection
[39]. All of these hypotheses deserve further study, partic-
ularly in high incidence settings.
In conclusion, our preliminary study, although limited by
numbers, raises the interesting hypothesis that in an envi-
ronment with ongoing, intensive nosocomial exposure,
HCWs may have high IFN-γ responses at baseline, and
continue to have persistently elevated T cell responses,
despite LTBI treatment. It is possible, although unproven
as yet, that persistence of infection and/or re-infection
might account for this phenomenon, and raises concerns
about efficacy of conventional preventive therapy in high
incidence settings with recurrent exposure. Further
research is needed to study T cell kinetics during LTBI
treatment, and determine the effect of repeated exposures
on host cellular immune responses, particularly in high
incidence settings. The availability of standardized, com-
mercial T cell-based IGRAs might greatly facilitate such
novel investigations.
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